Astellas' ASP0113 Trial Failure Gives Merck's Prevymis Further CMV Boost
Merck's Prevymis should benefit from the failure of ASP0113 in a late-stage trial treating cytomegalovirus in certain kidney transplant patients.
You may also be interested in...
Moderna raised $500m to fund its growing pipeline, choosing once again to stay private rather than pursue an IPO. Also, AvroBio closed a $60m Series B round to advance its gene therapies for lysosomal storage disorders, Seattle Genetics led recent public company financings, and Vical is restructuring.
The latest drug approval and development news from our US FDA Performance Tracker.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.